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Abstract
 
Analysis of a large number of unrelated bone marrow trans-
plantations (BMT) has shown that HLA-DP incompatibility
did not detectably influence the risk for acute graft-versus-
host disease (aGVHD). Accordingly, it was proposed that
HLA-DP determinants did not function as transplantation
antigens in the same way as HLA-A, -B, or -DR. We have
previously shown that HLA-DP (as well as HLA-A, -B, -DQ,
or -DR)-specific T cells could be isolated from skin biopsies
of patients who developed an aGVHD after semiallogeneic
BMT. Nevertheless, whether a single HLA-DP mismatched
allele could induce a detectable allo-specific reaction in vivo
after BMT remained to be established. To directly address
this issue we studied one patient who presented aGVHD af-
 
ter receiving purified CD34
 
1
 
 bone marrow (BM) cells from
an unrelated donor with a single HLA-DP mismatch in the
GVHD direction. To characterize the immunological events
associated with GVHD, we analyzed the peripheral T cell
repertoire, the T cell receptor V
 
b 
 
diversity, and the specific-
ity of T cells invading a skin biopsy at the onset of GVHD.
Our results demonstrated that a large fraction of skin-infil-
trating lymphocytes, which expressed diverse T cell recep-
tors, were reactive against this single HLA-DPB1*0501 mis-
match and consequently that a single HLA-DP mismatch
between BM donor and recipient can activate a strong T cell
response in vivo. (
 
J. Clin. Invest.
 
 1996. 98:100–107.) Key
words: skin 
 
•
 
 T lymphocytes 
 
•
 
 HLA-DP 
 
•
 
 clone 
 
•
 
 specificity
 
Introduction
 
Allogeneic bone marrow transplantation has become a suc-
cessful therapeutic approach for the treatment of several he-
matological malignancies as well as bone marrow failures such
as aplastic anemia. However, its success remains limited by
its chief complication: the acute graft-versus-host disease
(aGVHD)
 
1
 
 (1, 2). Two main risk factors are linked to the oc-
currence of aGVHD: the T cell content of the graft and the
HLA disparities between donor and recipient. With respect to
HLA disparities, the increased risk of aGVHD linked to
HLA-A, -B, -DR mismatching between donor and recipient is
well established (3–8), in contrast HLA-DP incompatibility
does not seem to be a risk factor for aGVHD (for review see
references 9 and 10). Accordingly, it was proposed that HLA-DP
determinants might not function as transplantation antigens in
the same way as HLA-A, -B, or -DR (10). In the absence of di-
rect evidence for HLA-DP recognition in such a graft situation,
we took advantage of a clinical situation where an acute
GVHD occurred in one of our patients who received an unre-
lated allogeneic bone marrow transplant (BMT) of CD34 puri-
fied precursor cells with a single HLA-DPB1*0501 mismatch
to address two questions: (
 
a
 
) could a single HLA-DPB1 allele
mismatch trigger a specific T cell response after BMT? and (
 
b
 
)
if a specific T cell response occurs, is it mediated by T cells ex-
pressing restricted T cell receptor V-
 
b
 
 (TCRBV) regions? In
the course of this study additional observations were made
concerning the relationship between T cells present in the skin
and the patient’s PBL at the onset of GVHD.
 
Methods
 
Case report
 
Patient.
 
A 48-yr-old female with chronic myeloid leukemia diag-
nosed in June 1990 was treated first with hydroxyurea, IFN-
 
a
 
 and
subcutaneous low dose cytarabine. In July 1993 she presented an ac-
celerated CML.
 
Bone marrow transplantation.
 
A search in the French Bone Mar-
row transplant registry detected one possible donor (host and donor
HLA typing are indicated in Table I). Results of mixed lymphocyte
culture was 8% in the GVH direction and 17% in the HVG direction.
The donor was a 20-yr-old male. Patient was CMV
 
1
 
; donor was
CMV
 
2
 
; they were ABO identical.
 
Conditioning regimen.
 
Total body irradiation: total dose 12 Gy
on six fractions over 3 d with lung shielding at 8 Gy followed by cyclo-
phosphamide 60 mg/kg/d on 2 consecutive d. Donor bone marrow
was harvested under general anesthesia.
 
Characteristics of the graft.
 
Because of GVHD risk factors (pa-
tient age, advanced disease, and unrelated donor), this patient re-
ceived, after informed consent, selected bone marrow (BM) CD34
 
1
 
cells with the aim of reducing GVHD risk through T cell reduction.
1,200 ml of whole marrow containing 5.31 
 
3
 
 10
 
8
 
 mononuclear cells /
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Abbreviations used in this paper:
 
 aGVHD, acute graft-versus-host
disease; BIL, biopsy-infiltrating cell line; BLCL, B lymphoblastoid
cell line; BM, bone marrow; BMT, BM transplant; GVL, graft-versus-
leukemia; TCRBV, T cell receptor V-
 
b
 
; TK, thymidine kinase.
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kg (27.6 
 
3
 
 10
 
9
 
 total) were harvested in heparinized flask from the
posterior iliac crest. A buffy coat was obtained by centrifugation us-
ing a Cobe 2991 blood cell processor (Cobe Laboratories Inc., Lake-
wood, CO). Nucleated cells (0.58 
 
3
 
 10
 
8
 
/kg) were stored unprocessed
as a reserve. Mononuclear cells (14.2 
 
3
 
 10
 
9
 
 total) including 1.70%
CD34
 
1
 
 cells (4.6 
 
3
 
 10
 
6
 
/kg) were then incubated with a biotinylated
anti-CD34 mAb (clone 12.8) for 25 min, washed in PBS; (Baxter, Mu-
nich, Germany) and processed onto a computer-driven avidin immu-
noaffinity column device (CEPRATE stem cell concentrator; Cell
Pro Inc., Bothell, WA). Adsorbed CD34
 
1
 
 cells were removed by me-
chanical agitation from the column, washed in PBS, diluted in 10 ml
PBS 4% HSA. The CD34
 
1
 
 fraction contained 3 
 
3
 
 10
 
6
 
 mononuclear
cells/kg (0.17 
 
3
 
 10
 
9
 
 total), including 54%, i.e 1.62 
 
3
 
 10
 
6
 
 CD34
 
1
 
 cells/
kg (recovery and enrichment for CD34
 
1
 
 cells were 35% and 32-fold,
respectively). CFU-GM content using standard assay was 4.79 
 
3
 
 10
 
6
 
,
total corresponding to 9.2 
 
3
 
 10
 
4
 
/kg. BFU-E content was 8.25 
 
3
 
 10
 
6
 
,
total corresponding to 15.87 
 
3
 
 10
 
4
 
/kg. CD34
 
1
 
 cells content was
92.4 
 
3
 
 10
 
6
 
, total corresponding to 1.78 
 
3
 
 10
 
6
 
/kg. Graft was injected
through a central venous line under 40 ml vol within 10 min on May 3,
1994. 
 
Evolution.
 
WBC was 
 
.
 
 1,000 on day 13, PMN 
 
.
 
 1,000 on day 14.
G-CSF (Granocyte) was started on day 7 at a dose of 263 
 
m
 
g/d i.v. No
evidence of platelet or erythrocyte reconstitution was observed until
death. No other GVHD prophylaxis except CD34
 
1
 
 selection was
used. Only 3% CD3
 
1
 
 T cells contaminated the CD34
 
1
 
 preparation
corresponding to a total number of T cell reinjected of 9.4 
 
3
 
 10
 
4
 
/kg.
On day 10, the patient presented a general skin eruption. A skin bi-
opsy was performed showing signs consistent with the diagnosis of
acute GVHD: vacuolization of keratinocytes with dermo-infiltration
with some lymphocytes. Immunophenotyping analysis showed a
strong expression of DR antigen on keratinocytes and the presence of
a mixed lymphocytic population composed of 30% CD4
 
1
 
 and 20%
CD8
 
1
 
 T cells. Treatment with Cyclosporine A 3 mg/kg/d CIV 
 
1
 
prednisone 4 mg/kg/d was started. Skin improved but liver function
decreased rapidly with diarrhea and rising bilirubin up to 
 
.
 
 600
mmol/liter at time of death. The patient died on day 39. The main
cause of death was aspergillosis complicating GVHD. Liver post mor-
tem examination showed signs compatible with GVHD. No evidence
of liver infection with aspergillosis was present.
 
VNTR analysis
 
DNA were prepared from host and donor B lymphoblastoid cell line
and digested by HaeIII. Digestion products were separated on a 1%
agarose gel, transferred onto hybond N
 
1
 
 membrane, and hybridized
with a hyper polymorphic single locus probe (PH30; Gibco BRL, Life
Technology, Gaithersburg, MD) labeled with 
 
l
 
CTP
 
32
 
.
 
Obtaining skin infiltrating T cells and clones
 
Skin specimens were washed at least five times in medium containing
10% pooled human sera, 1% 
 
l
 
-glutamine (2 mM), and 50 
 
m
 
g/ml gen-
tamycin and then cultured in a 24-well plate (Nunclon, Copenhagen,
Denmark) in the same medium supplemented with recombinant in-
terleukin 2 (rIL-2, 150 BRMP U/ml). Cultures were kept at 37
 
8
 
C in a
5% CO
 
2
 
 atmosphere. To generate a panel of clones, one responder T
cell was seeded in every three culture wells in 96-microwell round
bottom culture plate together with pooled allogeneic feeder cells (5 
 
3
 
10
 
4
 
 PBL and 5 
 
3
 
 10
 
3
 
 B lymphoblastoid cell line (BLCL), 30 gray irra-
diated) in the presence of 1 
 
m
 
g/ml leucoagglutinin-A (Pharmacia Fine
Chemicals, Uppsala, Sweden), and rIL-2 (150 BRMP U/ml). These
conditions, where 100% of T cells are stimulated, were chosen to
avoid in vitro antigenic selection. This allows the best representation
of T cells, which grew under rIL-2 alone during the initial culture pe-
riod, i.e., the in vivo activated T cells infiltrating the biopsy (11, 12),
since this procedure was shown to preserve the initial diversity of the
amplified population (13). Before specificity assays, clones were cul-
tured in IL-2 alone without stimulation for at least 3 wk. Because of
the limited number of biological material available, T cells from total
or CD34 purified BM cells as well as patient PBL were amplified for
10 d in vitro before T cell repertoire analysis using the polyclonal acti-
vation procedure described above.
 
Proliferation assay
 
Resting T cells (2.5–5 
 
3
 
 10
 
4
 
), taken 
 
.
 
 3 wk after the last stimulation,
were cocultured for 48–72 h with the indicated irradiated (30 Gy)
B-lymphoblastoid cell line (BLCL) in 96-microwell flat-bottomed
culture plates at a 1:1 responder-to-stimulator ratio. 6 h before har-
vesting, 1 
 
m
 
Ci of [
 
3
 
H]thymidine was added to each well, and 
 
3
 
H up-
take was then measured in a liquid scintillation counter. Results are
expressed as the mean of triplicate or quadruplicate cultures. Host,
donor, and the DAB BLCL, as well as the HLA-DPB1*0501 BLCL
DES, YOT, EGM, and BOV which were derived from genotyped
blood bank donors, were obtained by coculturing PBL with EBV
containing supernatant from the virus-producing B95.8 cell line in the
presence of 1 
 
m
 
g/ml CSA. The BLCL DEM, BH, QBL, E418, IBW9,
BSM, and HOM2 are from the 1987 HLA-workshop in New York.
 
Table I. HLA-typing of Host, Donor, and BLCL Used for the Study
 
BLCL HLA-A HLA-B HLA-DRB1 HLA-DQB1 HLA-DPB1
 
Host (Ho) 2 7/44 1501/1101 0602/0301 0401/0501
Donor (Do) 2 7/44 1501/1101 0602/0301 0301/0401
DES (A) 2/28 7 0103/0413 0501/0302 1501/0501
YOT (B) 1/23 44/12 4 nd 0202/0501
EGM (C) 1/11 51/7 1501/0407 nd 0401/0501
BOV (E) 3 7/62 15 nd W4/0501
DEM (F) 2.2 57.2 4/16 0502/0302 0401/1602
BH (G) 2.2 13.2 0701 0201 0401
QBL (I) 26.1 18.1 0301 0201 0202
E418 (J) 1 52 1502 0601 02012/0401
IBW9 (K) 33.1 65 0701 0201 0101
BSM (L) 2.2 62.3 0401 0302 02012
HOM2 3.2 27.5 1 0501 0401
DAB 2/11 18/W55 8/11 0402/0301 0401/1501
Letters between parentheses are used in Fig. 3 to refer to the corresponding BLCL. The two last cell lines HOM2 and DAB were used as controls in
the initial sceening of the clones presented in Table III. nd, not defined.
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The following mAbs were used for specificity studies: anti-HLA-DR
(GSP41), -DQ (1A3 or Leu-10), -DP (B7.21).
 
Flow cytometry
 
The following TCRBV region-specific mAbs (Immunotech, Marseille,
France) were used for flow cytometry: E2.2E7.2 (anti-BV2S1), LE89
(anti-BV3S1), IMMU157 (anti-BV5S1), 36213 (anti-BV5S2), OT145
(anti-BV6S7*1), 3G5D15 (anti-BV7S1), 56C5.2 (anti-BV8S1/S2), FIN9
(anti-BV9S1), C21 (anti-BV11S1), S511 (anti-BV12S1), IMMU1222
(anti-BV13S1), JU74 (anti-BV13S6), CAS1.1.13 (anti-BV14S1),
TAMAYA1.2 (anti-BV16S1), E17.5F3 (anti-BV17S1), BA62.6 (anti-
BV18S1), ELL1.4 (anti-BV20S1), IG125 (anti-BV21S3), IMMU546
(anti-BV22S1), and HUT78#1 (anti-BV23S1) (references compiled in
the 1995 TCR Workshop, San Francisco). Cells were stained by two
color immunofluorescence using phycoerythrin-conjugated CD3 (red
fluorescence) and unconjugated TCRBV region-specific mAb, whose
binding was revealed by FITC-conjugated goat anti–mouse IgG anti-
serum (green fluorescence). Labeled cells were analyzed on a FAC-
Scan (Beckton Dickinson and Co., Mountain View, CA) using LYSIS
II software.
 
Immunoscope analysis
 
TCR 
 
b
 
 chain-specific primers were as in reference 14 except for BV6
(5
 
9
 
 CTC TGA AGA TCC AGC GCA CAS AGC) and BV21 (5
 
9
 
TCC AGC CTG CAA AGC TTG AGG ACT). RNA was extracted
as previously described (14). Fluorescent DNA products were mi-
grated on sequencing gels in an automated DNA sequencer (Applied
Biosystems Inc., Foster City, CA), and raw data were analyzed by the
immunoscope software package (15, 16).
 
Results
 
Obtaining skin-infiltrating T cells.
 
The patient received 1.78 
 
3
 
10
 
6
 
 purified CD34
 
1
 
 cells/kg and T cell contamination was
0.94 
 
3
 
 10
 
5
 
/kg. 10 d after transplantation, a skin rash was ob-
served, and GVHD was suspected. A 4-mm skin punch biopsy
was performed and processed as described in Methods. After
3 d of culture, T cells started to exude the biopsy, and the biopsy
infiltrating cell line (BIL) was shown to proliferate specifically
against host BLCL but not against the irrelevant BLCL Boleth
and BTB, suggesting that at least a significant proportion of
these T cells were specific for host HLA antigens (data not
shown).
 
Analysis of T cell repertoire diversity before and after trans-
plantation.
 
Because of the limited number of reinjected T cells
and the presence of a single HLA-DP mismatch, T cell diver-
sity analysis represented in this case a particularly important
issue. Indeed, if a restricted T cell repertoire could be evi-
 
denced in such a graft setting, one could consider using specific
immunotherapy as an alternative to global immunosuppres-
sion. 
 
ab
 
 
 
T lymphocytes, the main effectors of the allogeneic re-
action, possess antigenic receptors whose variable regions are
made up of a combination of different TCR-V, -D, and -J ele-
ments (VDJ for 
 
b
 
 chains and VJ for 
 
a
 
 chains). Besides this
combinatorial diversity, a junctional diversity is produced by
the addition or removal of nucleotides at the junctions of the
rearranged genes. Combinatorial (TCR-V gene usage) and
junctional diversity of T cell receptors are now both amenable
to analysis: the former by using TCR-V region specific mAbs
and the latter by studying CDR3 length using recently devel-
oped techniques. An in depth TCR repertoire analysis was
performed among the following populations: the donor BM
CD3
 
1
 
 T cells before CD34 purification, the CD3
 
1
 
 T cells
contaminating the purified CD34
 
1
 
 precursor cells before in-
jection, the patient’s PBL on the day the biopsy was per-
formed, and the BIL.
TCRBV expression by the different T cell populations
mentioned above was first studied by two color flow cytometry
using an anti-CD3 mAb (red fluorescence) and mAbs specific
for a large set of TCRBV regions. On Table II is shown the
composition of the T cell repertoire detected in the different
populations. Total percentage of CD3
 
1
 
 cells recognized by
the panel of TCRBV-specific mAbs are indicated in the last
column. As one can see, on the day the biopsy was performed,
20 mAbs directed at variable TCRBV regions recognized alto-
gether only 8.7% of patient CD3
 
1
 
 PBL, compared to 62.6 and
57.5% of donor CD3
 
1
 
 PBL and CD3
 
1
 
 T cells contaminating
the CD34
 
1
 
 preparation, respectively. This proportion in-
creased with time and reached 38.0% on day 39 after trans-
plantation probably as a consequence of ongoing T cell repop-
ulation. Among BIL T cells, most TCRBV subsets were barely
detectable except for two which were clearly overexpressed
(TCRBV6S7, 9.6% and TCRBV22S1, 11.3%).
Taken together, these preliminary results indicated that
repertoire diversity among T cells contaminating the purified
CD34
 
1
 
 cell preparation was extensive and apparently not bi-
ased by the purification procedure. Of note, the two over-
represented subsets among BIL T cells (TCRBV6S7 and
TCRBV22S1) were only barely detectable among the patient’s
PBL tested on the day the biopsy was performed (PBLb on
Table II).
The T cell repertoire of these different T cell populations
was further investigated by analyzing the distribution of TCR
CDR3 length with a recently described technique termed Im-
 
Table II. Flow Cytometry Analysis of TCRBV Region Expression by the Different T Cell Populations Studied
 
TCR beta V Subsets (TCRBV)
2S1 3S1 5S1 5S2 5S3 6S7 8S1 11S1 12S2 13S1 13S6 14S1 16S1 17S1 18S1 19S1 21S3 22S1 T
 
Donor BM 6.3* 1.1 6.5 1.6 0.7 3.1 5.1 1.7 4.3 2.8 1.6 5.1 2.0 0.7 0.0 6.8 3.3 2.6 62.6
CD34c 4.2 0.3 4.5 0.8 0.9 1.7 4.2 0.9 1.5 2.4 1.4 8.9 1.2 0.5 0.3 7.0 2.9 2.2 57.5
PBLb 0.5 0.2 0.5 0.2 0.5 0.3 0.3 0.2 0.3 0.3 0.3 0.2 0.5 0.5 0.2 0.3 0.4 0.3 8.7
PBLd 0.3 0.5 5.7 0.7 1.5 2.0 1.9 0.3 2.0 0.8 6.5 5.7 0.4 0.2 0.0 4.1 4.3 1.1 38.0
BIL 0.3 0.0 0.3 0.4 0.0 9.6 2.7 0.2 1.5 0.4 nt 0.1 0.0 0.2 0.1 nt 0.1 11.3 27.3
*Percentage of positive cells (green fluorescence) among CD3
 
1
 
 T cells (red fluorescence); T, total percentage of the CD3
 
1 
 
T cell population recog-
nized; nt, not tested; PBLb, PBL harvested on day 10; PBLd, PBL harvested on day 39; BIL, Biopsy infiltrating lymphocytes (biopsy was performed
on day 10); square values correspond to subsets from which HLA-DP0501–specific T cell clones were obtained.
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munoscope (14). This sensitive technique, which involves a
combination of PCR and run off reactions using pairs of V
 
b
 
/
C
 
b
 
 primers followed by size determination of the elongation
products, allows efficient detection of oligoclonal T cell expan-
sion within each of the TCRBV subsets studied. As shown on
Fig. 1, a Gaussian-like distribution of CDR3 length was ob-
served for most TCRBV chain genes expressed by either do-
nor BM or CD34 contaminating T cells, demonstrating a high
degree of diversity within these T cell populations. In contrast,
dramatic alterations in CDR3 length distribution were de-
tected for both the patient PBLb and the BIL T cell–derived
cDNA amplified with several primers, e.g., BV5, BV6, BV7,
BV9, BV13, BV17, BV19, BV21, BV22, and BV23, for the
PBL, and all of them for the BIL T cells. These data confirmed
and extended the flowcytometry results obtained with TCRBV-
specific mAbs. It is noteworthy that isolated peaks with the
same CDR3 length were detected for TCRBV13 and TCRBV19
among both PBLb and BIL T cells. As already suggested by
others (17, 18), these peaks most likely represented the same T
cell subsets or clones, although a formal demonstration would
require direct sequencing of their TCR VDJB junctions. In
contrast, most of the other BIL subsets with restricted CDR3
length could not be spotted by this sensitive technique among
the patient’s PBL. Consequently, all T cell repertoire alter-
ations found among PBL do not necessarily reflect T cell ex-
pansions occurring concomitantly at the site of aGVHD.
 
Origin and specificity of clones derived from BIL T lym-
phocytes.
 
We then analyzed the specificity of skin-infiltrating
T cells at the clonal level. Clones were derived from BIL by
limiting dilution as described in Methods. 62 clones were
screened for CD4/CD8 and TCRBV usage with specific mAbs
(see Table II). Clones were derived from the following subsets:
TCRBV5S2 (n 5 2), TCRBV6S7 (n 5 7), TCRBV8S1 (n 5 9),
TCRBV17S1 (n 5 1), TCRBV13S1 (n 5 2), and TCRBV22S1
(n 5 7), (squared values on Table II). 23 clones (referred to as
TCRBVX) were not recognized by the available TCRBV-spe-
cific panel of mAbs. Among the TCRBVX host-specific T cell
clones only one was kept for further functional study. Clones
belonging to a given TCRBV subset were particularly homo-
geneous since they expressed the same co-receptor and had
the same reactivity pattern (Table III). Indeed all BV61,
BV131, BV221, and BV51 clones were host reactive (as well
as the single BV171) while none of the BV81 recognized the
host BLCL (Table III). Together with data from immunoscope
analysis which evidenced a unique or dominant peak within
each of the BIL TCRBV subsets (Fig. 1), these results strongly
suggested that each set of clones belonging to the same
TCRBV family derived in fact from a single or a few T cell
clones. These findings are also in agreement with our previous
reports showing that T cells infiltrating the skin at the onset of
GVHD were oligoclonal, and for a majority of them, host spe-
cific (11, 12). Consequently, one clone representative of each
subset was kept for further characterization.
First, DNA from TCRBV5S2, TCRBV6S7*1, TCRBV8S1,
TCRBV13S1, TCRBV22S1, and three TCRBVX T cell clones
were compared to DNA from host or recipient BLCL using
RFLP analysis to determine whether they originated from host
or donor. Results, shown on Fig. 2, demonstrated that all
clones tested originated from the donor.
We next tested these clones against host and donor BLCL
Figure 1. Distribution of CDR3b size (immunoscope profiles) within donor BM cells (Donor BM), T cells contaminating the CD34 inoculum 
(CD341c), patient PBL harvested the day the biopsy was performed (PBLb) and within the skin biopsy derived T cell line (BIL). Note that 
HLA-DPB1*0501–specific T cell clones were derived from the BIL TCRBV5S2, 6S7, 13S1, and 22S1 T cell subsets and that the peak observed 
for Vb13 within PBLb and BIL most likely corresponded to the HLA-DPB1*0501–specific T cell clone derived from the BIL and having the 
same CDR3 size (data not shown).
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as well as against a panel of genotyped BLCL bearing or not
the HLA-DPB1*0501 mismatched allele in the GVHD direc-
tion. As shown in Fig. 3 each clone tested specifically recog-
nized host BLCL and, among allogeneic ones, only those bear-
ing the HLA-DPB1*O501 allele (Fig. 3, top, and Table I for
extensive HLA typing of host donor and target BLCL). Ac-
cordingly, proliferation of each clone against a stimulating
BLCL was blocked by an HLA-DP–specific mAb but re-
mained unaffected by the addition of mAb against HLA-DQ
or -DR. Of note, reactivity against HLA-DPB1*0501 of the
CD81 TCRBV5S2 T cell clone was also demonstrated using
this large panel of BLCL. Moreover, this CD81 TCRBV5S2
as well as the CD41 TCRBV22S1 T cell clone were found cy-
totoxic against HLA-DPB1*0501 bearing BLCL (data not
shown). No other reactivity than the one directed at HLA-
DPB1*0501 was evidenced.
Discussion
We have recently documented the presence of HLA-DP–spe-
cific T cells in the skin lesions of patients who developed
GVHD after semiallogeneic BMT (11, 12). In these previous
examples, other HLA class I and class II incompatibilities
were present in addition to the HLA-DP mismatch. Thus,
these other mismatches could have contributed to the initiat-
ing of the response against HLA-DP. To the best of our
knowledge, no biological data were yet available concerning
the ability of an isolated HLA-DPB1 mismatched allele to in-
duce a specific alloreaction in vivo. In the present paper we
provide evidence that after an allogeneic transplantation with
a single HLA-DPB1*O501 mismatch between donor and re-
cipient, a large proportion of the skin-infiltrating T cells were
HLA-DPB1*O501–specific. These data conclusively demon-
strate the occurrence of an in vivo alloreaction against this iso-
lated mismatched allele. Because these T cells clones were de-
rived from a skin lesion, our data also strongly suggest a direct
involvement of HLA-DP in the pathogenesis of GVHD. Nev-
ertheless, it has long been established that alloreactivity
against MHC molecules is not the only factor conditioning
GVHD since the 1–3% occurrence of DR/DQ and DP recom-
bination cannot account for the 20–50% of GVHD reported
between genotypically identical siblings (1). Moreover, the
contribution of minor histocompatibility antigens to the in-
creased risk of GVHD has been recently demonstrated (19).
Because minor histocompatibility antigens disparity is bound
to be significantly greater between unrelated than between
Table III. Screening of Clones Derived from BIL T Cells
Stimulator BLCL (cpm)
Clone # none HOM2 HOST DAB TCRBV CD4/8
none 2 407 1536 578 2
3 534 588 25778 1108 TCRBV6S7 CD4
6 291 407 10409 951 " "
7 2994 3023 29992 5124 " "
17 255 453 8284 1022 " "
23 530 398 16389 1253 " "
26 307 873 12156 3217 " "
32 295 363 33857 819 " "
35 691 980 12938 1898 " "
40 5658 5377 30056 5616 " "
46 160 327 9088 881 " "
52 6663 3137 28112 2524 " "
57 283 556 10624 1269 " "
61 86 54 21818 942 " "
20 170 373 1161 896 TCRBV8S1 CD4
21 570 500 1182 936 " "
24 96 375 1387 974 " "
39 150 317 1066 1110 " "
44 253 381 1166 873 " "
51 188 548 1112 733 " "
56 237 327 735 988 " "
63 160 277 943 992 " "
65 1458 265 3450 2858 " "
12 1586 1281 11436 1803 TCRBV13S1 CD4
48 851 773 6631 1560 " "
22 727 994 4801 1000 TCRBV17S1 CD4
4 395 426 7230 881 TCRBV22S1 CD4
11 395 431 11065 1076 " "
25 202 281 5896 751 " "
33 122 345 8077 821 " "
34 128 351 21764 805 " "
38 3522 6470 21986 6947 " "
58 363 263 13965 914 " "
18 11177 4770 15828 6331 TCRBV5S2 CD8
55 1872 1462 20809 2904 " "
Each T cell clone obtained by limiting dilution from BIL culture was
screened for CD4, CD8, and for the five TCRBV-specific mAbs recog-
nizing the most frequent subsets among BIL cells (see Table II). Clones
were tested in a 72-h proliferation assay against host and two unrelated
BLCL (HOM2 and DAB).
Figure 2. RFLP analysis of clones belonging to each of the TCRBV 
subsets detected among skin infiltrating T cells. Donor and recipient 
DNA were clearly identified by alleles of different sizes; all clones are 
of donor origin.
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genoidentical individuals (20), it is likely that specific T cells
directed against minor antigens also contribute to the in-
creased risk of GVHD after unrelated bone marrow transplan-
tation. Thus, it is difficult to ascertain that the HLA-
DPB1*0501–specific T cells we described were the only ones
to participate in the GVHD process. In our protocol, the T cell
clones derived from the skin biopsy were screened for their
ability to proliferate against host BLCL. Because it has been
shown that BLCL might not present MHC class II restricted
minor antigens adequately (21), it is possible that some of the
T cell clones found negative against host BLCL were in fact
specific for host MHC class II restricted minor antigens. Aside
from their specificity, the pathological consequences of host
recognition by T cells is dependent not only on the total num-
ber of cells involved and the strength of the effector-target in-
teraction, but also on the “context” in which such recognition
occurs (underlying disease, preparative regimen, treatments).
The case presented demonstrates that a single HLA-DP mis-
match is able to initiate an in vivo alloreaction and therefore
contributes to that part of the pathological process which de-
pends upon the specific T cell response.
It is now clear that GVHD is not the only consequence of
host cells recognition by donor T lymphocytes. This alloreac-
tion also has a beneficial effect termed graft-versus-leukemia
reaction (GVL). Evidence for GVL comes mainly from clini-
cal studies showing the balance between these two aspects of
the allogeneic reaction: patients who experienced GVHD had
fewer relapses than patients without GVHD, but only patients
with a mild degree of GVHD had a survival advantage (22–24).
Although GVH and GVL are both mediated by donor T lym-
phocytes, it is yet impossible to discriminate the subsets that
are responsible for one or the other. As a consequence, most
of the recent efforts to control the alloreaction (i.e., to keep
the benefit from the GVL effect while avoiding the mortality
and morbidity due to GVHD) have focused on the trans-
planted T cell as a whole (25): for example, some groups have
considered the reinjection of graded doses of donor T cells
(26), and more recently it was proposed to transduce donor
Figure 3. Determination of specificity for TCRBV se-
lected clones: each clone recognized host BLCL (Ho) 
but not the donor BLCL (Do). Moreover they also rec-
ognized the 4 HLA-DPB1*0501–positive BLCL (A, B, 
C, and E, see Table I for HLA typing) but not the 
HLA-DPB1*0501–negative BLCL F, G, I, J, K, L ex-
cept the TCRBV5S2 CD81 clones which also cross-
react with J (top). Recognition of target BLCL was 
blocked by mAb against HLA-DP (B7.21) but not by 
mAb against HLA-DQ (Leu-10) or HLA-DR 
(GSP41).
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T cells with the herpes-simplex thymidine kinase (TK) gene
before grafting (27). Because the viral TK is able to phosphor-
ylate the nucleoside analogue ganciclovir, resulting in the pro-
duction of metabolites toxic for mammalian cells, its transfer
into T cells renders them sensitive to ganciclovir and allows
their destruction through ganciclovir treatment (28). In line
with these concerns, how can we take advantage of these two
apparently paradoxical observations: HLA-DP incompatibility
does not significantly influence the risk of acute GVHD (9,
10), yet HLA-DP specific T cells can be isolated from skin bi-
opsies at the onset of GVHD each time an HLA-DP mismatch
is present (11, 12, and this report). If an HLA-DP mismatch is
able to induce an allogeneic response in vivo it should be able
to trigger both a GVH and a GVL effect (as long as the leuke-
mic cells express the HLA-DP antigens, of course). Indeed, we
are currently considering the use of HLA-DPB1–specific T
cell clones, transfected with the viral TK gene and directed
against a HLA-DPB1 mismatch allele in the GVH direction
(to spare the new hematopoiesis from the graft) to generate an
allogeneic GVH-GVL effect in the context of a T cell–
depleted BMT. Targeting an HLA-DP mismatch in the GVH
direction to generate an allogeneic effect has two main advan-
tages. Firstly, because 70% of HLA-A, -B, -DR identical BMT
are HLA-DP mismatched, HLA-DP targeting would allow the
consideration of a phase I clinical trial in an otherwise immu-
nologically classic BMT. Moreover, although one would spon-
taneously tend to use autologous T cell clones for such an ap-
plication, it may become possible to consider the use of third
party specific T cell clones in this very particular clinical situa-
tion, because of the drastic immunodepression associated with
a T cell–depleted BMT. In addition, immune recognition of
the clone by T cells arising from the graft can also be dimin-
ished if the clones of interest are derived from individuals ho-
mozygous for widely represented HLA molecules such as
HLA-A1, -B8, -DR3, -DQ2. If third party T cell clones prove
useful, the second advantage comes from the fact that the five
most frequent HLA-DPB1 alleles (HLA-DPB1*0401, 402,
101, 201, 301) cover . 80% of the Caucasian population. Con-
sequently, a few clones would allow the treatment of a major-
ity of patients. In line with this approach, we have recently
demonstrated the feasibility of generating HLA-DPB1*0401–
specific CD41 cytotoxic T cell clones transfected by electropo-
ration with a neutral vector containing the herpes-simplex TK
gene. These clones retained their specificity, their function,
and their sensitivity to ganciclovir treatment (29). In conclu-
sion, we propose that such clones could be considered as po-
tential therapeutical tools to drive and control a GVH-GVL
reaction.
Acknowledgments
The authors wish to thank Odile Herbert for expert technical assis-
tance, Béatrice Mahé, and Francois Lang for critical reading of the
manuscript.
This work was supported by an institutional grant from INSERM
and by the EEC grant BIO2 CT.920300.
References
1. Ferrara, J.L.M., and H.L. Deeg. 1991. Graft-versus-host disease. N. Engl.
J. Med. 324:667–674.
2. Beatty, P.G., J.A. Hansen, G.M. Longton, E.D. Thomas, J.E. Sanders,
P.J. Martin, S.I. Bearman, C. Anasetti, E.W. Petersdorf, E.M. Mickelson, et al.
1991. Marrow transplantation from HLA-matched unrelated donor for hema-
tologic malignancies. Transplantation (Baltimore). 51:443–447.
3. Ash, R.C., J.T. Casper, C.R. Chitambar, R. Hansen, N. Bunin, R.L. Tru-
itt, C. Lawton, K. Murray, J. Hunter, L.A. Baxter-Lowe, et al. 1990. Successful
allogeneic transplantation of T-cell depleted bone marrow from closely HLA-
matched unrelated donors. N. Engl. J. Med. 322:485–494.
4. Anasetti, C., P.G. Beatty, R. Storb, P.J. Martin, M. Mori, J.E. Sanders,
E.D. Thomas, and J.A. Hansen. 1990. Effect of HLA incompatibility on graft-
versus-host disease, relapse and survival after marrow transplantation for pa-
tients with leukemia or lymphoma. Hum. Immunol. 29:79–87.
5. Beatty, P.G., R.A. Clift, E.M. Mickelson, B. Nisperos, N. Flournoy, P.J.
Marin, J.E. Sanders, R. Storb, E.D.Thomas, and J.A. Hansen. 1985. Marrow
transplantation from related donors other than HLA-identical siblings. N. Engl.
J. Med. 313:765–771.
6. Hansen, J.A., C. Anasetti, P.G. Beatty, P.J. Martin, J.E. Sanders, R.
Storb, and E.D. Thomas. 1990. Treatment of leukemia by marrow transplanta-
tion from HLA-incompatible donors. Effect of HLA-disparity on GVHD, re-
lapse and survival. Bone Marrow Transplant. 6:108–111.
7. Storb, R., H.J. Deeg, J. Whitehead, F. Appelbaum, P.B. Beatty, W. Bens-
inger, C.D. Buckner, R. Clift, K. Doney, V. Farewell, J.A. Hansen, et al. 1986.
Methotrexate and cyclosporine compared with cyclosporine alone for the treat-
ment of acute graft versus host disease after marrow transplantation for leuke-
mia. N. Engl. J. Med. 314:729–735.
8. Beatty, P.G., C. Anasetti, J.A. Hanse, G.M. Longton, J.E. Sanders, P.J.
Marin, E.M. Mickelson, S.Y. Choo, E.W. Petersdorf, M.S. Pepe, F.R. Appel-
baum, et al. 1993. Marrow transplantation from unrelated donors for treatment
of hematologic malignancies: effect of mismatching of one HLA locus. Blood.
81:249–253.
9. Moreau, P., and A. Cesbron. 1994. HLA-DP and allogeneic bone marrow
transplantation. Bone Marrow Transplant. 13:675–681.
10. Petersdorf, E.W., A.G. Smith, E.M. Mickelson, G.M. Longton, C. Ana-
setti, S.Y. Choo, P.J. Martin, and J.A. Hansen. 1993. The role of HLA-DPB1
disparity in the development of acute graft-versus-host disease following unre-
lated bone marrow transplantation. Blood. 81:1923–1932.
11. Gaschet, J., B. Mahe, N. Milpied, M.C. Devilder, B. Dreno, J.D. Bignon,
F. Davodeau, M.M. Hallet, M. Bonneville, and H. Vié. 1993. Specificity of T
cell invading the skin during acute graft versus host disease after semi alloge-
neic bone marrow transplantation. J. Clin. Invest. 91:12–20.
12. Gaschet, J., M.A. Trevino, M. Cherel, R. Vivien, A.G. Sahuquillo, M.M.
Hallet, M. Bonneville, J.L. Harrousseau, R. Bragado, N. Milpied, and H. Vié.
1996. HLA-target antigens and TCR diversity of activated T cells invading the
skin during acute graft versus host disease. Blood. 87:2345–2353.
13. Gaschet, J., C. Denis, N. Milpied, M.M. Hallet, F. Davodeau, A.
Necker, F. Romagne, M. Bonneville, and H. Vié. 1995. Analysis of T-cell recep-
tor Vb expression among Va subsets. Evidence for tight regulation of the com-
binatorial diversity. Ann. NY Acad. Sci. 756:84–86.
14. Even, J., A. Lim, I. Puisieux, L. Ferradini, P.Y. Dietrich, A.Toubert, T.
Hercend, F. Triebel, C. Pannetier, and P. Kourilsky. 1996. T cell repertoire in
healthy and diseased human tissues analysed by T cell receptor b chain CDR3
size determination: evidence for clonal expansions in tumors and inflammatory
diseases. Res. Immunol. 146:65–80.
15. Pannetier, C., S. Delassus, S. Darche, C. Saucier, and P. Koutilsky. 1993.
Quantitative titration of nucleic acids by enzymatic amplification reactions run
to saturation. Nucleic Acids Res. 21:577–583.
16. Pannetier, C., M. Cochet, S. Darche, A. Casrouge, M. Zoller, and P.
Kourilsky. 1993. The size of the CDR3 hypervariable regions of the murine T
cell receptor b chain vary as a function of the recombined germline segments.
Proc. Natl. Acad. Sci. USA. 90:4319–4323.
17. Dietrich, P.Y., A. Caignard, A. Diu, C. Genevee, J.L. Pico, M. Henry-
Amar, E. Angevin, F. Triebel, and T. Hercend. 1990. Analysis of T cell receptor
variability in transplanted patients with graft-versus-host disease. Blood. 80:
2419–2424.
18. Dietrich, P.Y., A. Caignard, Y. Lim Chung, J.L. Pico, C. Pannetier, P.
Kourilsky, T. Hercent, and F. Triebel. 1994. In vivo clonal amplification at time
of acute graft-versus-host disease. Blood. 84:2815–2820.
19. Goulmy, E., R. Shipper, J. Pool, E. Blokland, J.H.F. Falkenburg, J. Vos-
sen, A. Gratwohl, G.B. Vogelsang, H.C. van Houwelingen, and J.J. van Rood.
1996. Mismatches of minor histocompatibility antigens between HLA-identical
donors and recipients and the development of graft-versus-host disease after
bone marrow transplantation. N. Engl. J. Med. 334:281–285.
20. Martin, P.J. 1991. Increased disparity for minor histocompatibility anti-
gens as a potential cause of increased GVHD risk in marrow transplantation
from unrelated donors compared with related donors. Bone Marrow Trans-
plant. 8:217–225.
21. van Lochem, E.G., A. Bakker, S. Snijder, M. Aarts, G.C. de Gast, and
E. Goulmy. 1995 Epstein-Barr virus infection abrogates the stimulatory capac-
ity of B cells to a major histocompatibility complex class II-restricted prolifera-
tive T cell clone. Hum. Immunol. 42(2):137–144.
22. Apperley, J.F., F.R. Mauro, J.M. Goldman, W. Gregory, C.K. Arthur, J.
Hawks, W. Arcese, G. Papa, F. Mandelli, D. Wardle, et al. 1988. Bone marrow
transplantation for chronic myelogenous leukemia in first chronic phase: Im-
portance of a graft-versus-leukemia effect. Br. J. Haematol. 69:239–246.
Graft Versus Host Disease and HLA-DP 107
23. Weiden, P.L., K.M. Sullivan, N. Flournoy, R. Storb, and E.D. Thomas.
1981. The Seattle Marrow Transplant Team: antileukemic effect of chronic
graft-versus-host disease. Contribution for improved survival after allogeneic
marrow transplantation. N. Engl. J. Med. 304:1529–1532.
24. Horowitz, M.M., R.P. Gale, P.M. Sondel, J.M. Goldman, J. Kersey, H.J.
Kolb, A.A. Rimm, O. Ringden, C. Rozman, B. Speck, et al. 1990. Graft-versus-
leukemia reaction after bone marrow transplantation. Blood. 75:555–562.
25. Kolb, H.J., A. Schattenberg, J.M. Goldman, B. Hertenstein, N. Jacob-
sen, W. Arcese, P. Ljungman, A. Ferrant, L. Veronck, D. Niederwieser, et al.
1995. For the European group for blood and marrow transplantation. Graft-
versus-leukemia effect of donor lymphocyte transfusion in marrow grafted re-
cipients. Blood. 86:2041–2050.
26. MacKinnon, S., E.B. Papadopoulos, M.H. Carabasi, L. Reich, N.H. Col-
lins, F. Boulal, H. Castro-Malaspina, B.H. Childs, A.P. Gillio, N.A. Kernan, et
al. 1995. Adoptive immunotherapy evaluating escalating doses of donor leuko-
cytes for relapse of chronic myeloid leukemia after bone marrow transplanta-
tion: separation of graft-versus-leukemia responses from graft-versus-host dis-
ease. Blood. 86:1261–1268.
27. Tiberghien, P., C.W. Reynolds, J. Keller, S. Spence, M. Deschaseaux,
J.M. Certoux, E. Contassot, W.J. Murphy, R. Lyons, Y. Chiang, et al. 1994.
Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary
T lymphocytes: an approach for specific in vivo donor T-cell depletion after
bone marrow transplantation. Blood. 84:1333–1341.
28. Borelli, E., R. Heyman, M. Hsi, and R.M. Evans. 1988. Targeting of an
inducible toxic phenotype in anomal cells. Proc. Nat. Acad. Sci. USA. 85:7572–
7576.
29. Gallot, G., M.M.H. Hallet, J. Gashet, J.M. Moreau, R. Vivien, M. Bon-
neville, N. Milpied, and H. Vié. 1996. Human HLA-specific T cell clone with
stable expression of a suicide gene: a possible tool to drive and control a GVH-
GVL reaction. Blood. In press.
